Data from Viral Kinetic Study Showed Rapid Reduction of HCV RNA with ALS-2200 (VX-135), Vertex's Ora
Data from Viral Kinetic Study Showed Rapid Reduction of HCV RNA with ALS-2200 (VX-135), Vertex's Oral Nucleotide Analogue in Development for the Treatment of Hepatitis C - 4.54 log 10 median reduction ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 11 abstracts from its hepatitis C research and development program will be presented at The ...
Aim is to combine ALS-2200 and ALS-2158 with approved Incivek and investigational candidate VX-222. Vertex Pharmaceuticals is paying Alios BioPharma $60 million up front for worldwide rights to two of ...
Vertex Announces Presentation of New Data from Hepatitis C Development Program at AASLD Annual Meeti
1. "ALS-2200, a Novel Once-Daily Nucleotide HCV Polymerase Inhibitor, Demonstrates Potent Antiviral Activity over 7 Days in Treatment-Naïve Genotype 1 (GT1) Patients." November 11, 2012, 5:00 p.m. EST ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on ALS-2200 (VX-135), an oral medicine Vertex is developing for the treatment of hepatitis C, are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback